🇺🇸 Silodosin Capsules in United States

16 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 4 reports (25%)
  2. Blood Pressure Decreased — 2 reports (12.5%)
  3. Headache — 2 reports (12.5%)
  4. Product Substitution Issue — 2 reports (12.5%)
  5. Aphasia — 1 report (6.25%)
  6. Beta 2 Microglobulin Urine Increased — 1 report (6.25%)
  7. Beta-N-Acetyl-D-Glucosaminidase Increased — 1 report (6.25%)
  8. Cardiac Failure Acute — 1 report (6.25%)
  9. Cerebrovascular Accident — 1 report (6.25%)
  10. Chest Pain — 1 report (6.25%)

Source database →

Silodosin Capsules in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Silodosin Capsules approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Silodosin Capsules in United States?

Xintian Pharmaceutical is the originator. The local marketing authorisation holder may differ — check the official source linked above.